ATE423556T1 - Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen - Google Patents

Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen

Info

Publication number
ATE423556T1
ATE423556T1 AT02736910T AT02736910T ATE423556T1 AT E423556 T1 ATE423556 T1 AT E423556T1 AT 02736910 T AT02736910 T AT 02736910T AT 02736910 T AT02736910 T AT 02736910T AT E423556 T1 ATE423556 T1 AT E423556T1
Authority
AT
Austria
Prior art keywords
composition
abuse
capsaicin
pharmaceutical compositions
compositions containing
Prior art date
Application number
AT02736910T
Other languages
English (en)
Inventor
Michael Goldberg
Bradley Galer
Huai-Hung Kao
Original Assignee
Endo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Pharmaceuticals Inc filed Critical Endo Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE423556T1 publication Critical patent/ATE423556T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02736910T 2001-05-23 2002-05-16 Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen ATE423556T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29280901P 2001-05-23 2001-05-23

Publications (1)

Publication Number Publication Date
ATE423556T1 true ATE423556T1 (de) 2009-03-15

Family

ID=23126288

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02736910T ATE423556T1 (de) 2001-05-23 2002-05-16 Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen

Country Status (10)

Country Link
US (1) US20030064122A1 (de)
EP (1) EP1392270B1 (de)
JP (2) JP4315687B2 (de)
CN (1) CN1511030A (de)
AT (1) ATE423556T1 (de)
AU (1) AU2002309885B2 (de)
CA (1) CA2447807C (de)
DE (1) DE60231298D1 (de)
ES (1) ES2321589T3 (de)
WO (1) WO2002094254A2 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
EP1404333A1 (de) * 2001-07-06 2004-04-07 Endo Pharmaceuticals Inc. Kontrolliert freisetzende formulierungen von oxymorphon
WO2003004033A1 (en) * 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
WO2003039561A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
WO2003092676A1 (en) * 2002-04-29 2003-11-13 The General Hospital Corporation Compositions and methods for preventing abuse of orally administered medications
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040109886A1 (en) * 2002-08-27 2004-06-10 Larry Rigby Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent
SI1551372T1 (en) * 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
CA2499994C (en) * 2002-09-23 2012-07-10 Verion, Inc. Abuse-resistant pharmaceutical compositions
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE602004024963D1 (de) 2003-03-13 2010-02-25 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
AU2004235794B8 (en) * 2003-04-30 2009-07-23 Purdue Pharma L.P. Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
EP2112920B1 (de) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006044805A2 (en) * 2004-10-15 2006-04-27 Supernus Pharmaceuticals, Inc. Less abusable pharmaceutical preparations
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
KR20080007378A (ko) * 2005-04-25 2008-01-18 노이로제스엑스, 인코포레이티드 Ｔｒｐｖ1 작용제 화합물 및 이것의 제조 및 사용 방법
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2719378B1 (de) * 2006-06-19 2016-08-31 Alpharma Pharmaceuticals LLC Pharmazeutische Zusammensetzungen
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US20080226702A1 (en) * 2007-03-16 2008-09-18 Endo Pharmaceuticals, Inc. Transdermal Delivery Form Disposal Systems and Methods
WO2008131256A1 (en) * 2007-04-19 2008-10-30 Trinity Laboratories Inc. Improved treatments for premature ejaculation in humans
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
CN101969930A (zh) * 2007-12-17 2011-02-09 莱博法姆公司 防滥用控制释放制剂
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2224808A4 (de) * 2007-12-17 2013-11-27 Alpharma Pharmaceuticals Llc Pharmazeutische zusammensetzung
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
EP2367541B1 (de) 2008-12-16 2014-07-16 Paladin Labs Inc. Formulierung mit gesteuerter freisetzung und missbrauchsschutz
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
CN103179954A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
CA2991216C (en) 2010-12-22 2020-04-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
PL2736497T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
ES2691982T3 (es) 2012-11-30 2018-11-29 Acura Pharmaceuticals, Inc. Liberación autorregulada de un principio activo farmacéutico
AP2015008579A0 (en) 2013-02-05 2015-07-31 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
US10092528B2 (en) 2013-03-13 2018-10-09 Altria Client Services Llc Application of encapsulated capsaicin and analogues thereof for controlling calorie intake
US9517208B2 (en) 2013-03-15 2016-12-13 Purdue Pharma L.P. Abuse-deterrent dosage forms
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9616029B2 (en) 2014-03-26 2017-04-11 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (de) 2014-05-26 2017-04-05 Grünenthal GmbH Gegen entsorgung von ethanolischer dosis gesicherte mehrfachpartikel
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3193873A4 (de) * 2014-09-15 2018-05-30 Inspirion Delivery Technologies, LLC Oral verabreichbare zusammensetzungen und verfahren zur verhinderung des missbrauchs durch intranasale verabreichung
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681897A (en) * 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4898887A (en) * 1984-12-20 1990-02-06 The Procter & Gamble Company Compounds and compositions having anti-inflammatory and analgesic activity
US5383848A (en) * 1990-04-12 1995-01-24 Gensia, Inc. Iontophoretic administration of drugs
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5762963A (en) * 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms

Also Published As

Publication number Publication date
JP4315687B2 (ja) 2009-08-19
DE60231298D1 (de) 2009-04-09
WO2002094254A3 (en) 2003-03-27
JP2005515153A (ja) 2005-05-26
CA2447807A1 (en) 2002-11-28
ES2321589T3 (es) 2009-06-09
AU2002309885B2 (en) 2007-11-01
CA2447807C (en) 2009-10-13
JP2009149696A (ja) 2009-07-09
EP1392270A2 (de) 2004-03-03
US20030064122A1 (en) 2003-04-03
EP1392270B1 (de) 2009-02-25
WO2002094254A2 (en) 2002-11-28
CN1511030A (zh) 2004-07-07

Similar Documents

Publication Publication Date Title
ATE423556T1 (de) Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen
GEP20022851B (en) Flash-Melt Oral Dosage Formulation
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
EP1685839B8 (de) Peroral zu verabreichende Arzneiform enthaltend eine Kombination von einem Opioid-Agonisten und einem Opioid- Antagonisten
NO20022058D0 (no) Farmasöytiske sammensetninger
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
MX2007000008A (es) Formas farmaceuticas orales, protegidas frente al abuso, que contienen (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil) fenol.
SG147485A1 (en) Pharmaceutical compositions for prevention of overdose or abuse
WO2003015531A3 (en) Pharmaceutical formulation containing dye
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
MY127350A (en) Flash-melt oral dose formulations
PT1411921E (pt) Composições farmacêuticas contendo terbinafina e suas utilizações
MXPA05013392A (es) Composiciones farmaceuticas de atorvastatina.
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
CY1107295T1 (el) Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους
MY144297A (en) Pharmaceutical compositions
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
GEP20043377B (en) Pharmaceutical Complex
SE0000303D0 (sv) Novel compounds
ITMI20011446A0 (it) Composizioni farmaceutiche di principi attivi suscettibili di somministrazione illecita
MXPA02006034A (es) Formas de dosis mucosaloral de apomorfina.
SE0203817D0 (sv) New composition
RU2002126216A (ru) Фармацевтическая композиция для лечения и профилактики фиброза и цирроза печени

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties